Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hemophilia B (Factor IX) (Apr 2021)

Posted by Matt Breese on Apr 23, 2021

Find me on:

According to our recent payer coverage analysis for hemophilia B (factor IX) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hemophilia B (factor IX) treatments shows that under the pharmacy benefit, about 37% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Hemophilia B-2Q2021Data snapshot as of Q2 2021

Trends: Anticipated product approvals may develop improved product placement based on potential cost, adherence and efficacy advantages. The hemophilia market will be managed more tightly as we start seeing an increase in long-acting products.    

To read the full Reality Check on Hemophilia B (Factor IX) treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing